Reports Q4 revenue $135.4M, consensus $123.96M. “We returned to revenue growth, significantly improved adjusted EBITDA, and further enhanced our liquidity position as a result of our team’s strong execution in the fourth quarter of 2023,” commented Rob Claypoole, Bioventus’ President and Chief Executive Officer. “After immersing myself in the business over the last two months, it’s clear to me that Bioventus has a solid foundation of market-leading products and compelling growth prospects. Going forward, we remain committed to unlocking our full potential to help patients and create value for shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BVS:
- Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
- Bioventus Amends Credit Agreement with Enhanced Covenants
- Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
- Bioventus amends credit, guaranty agreement
- Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
